Purpose To develop a technique that maximizes the encapsulation of functional proteins within neutrally charged, fully PEGylated and nanoscale polymer vesicles (i.e., polymersomes). Methods Three conventional vesicle formation methods were utilized for encapsulation of myoglobin (Mb) in polymersomes of varying size, PEG length, and membrane thickness. Mb concentrations were monitored by UV-Vis spectroscopy, inductively coupled plasma optical emission spectroscopy (ICP-OES) and by the bicinchoninic acid (BCA) assay. Suspensions were subject to protease treatment to differentiate the amounts of surface-associated vs. encapsulated Mb. Polymersome sizes and morphologies were monitored by dynamic light scattering (DLS) and by cryogenic transmission electron microscopy (cryo-TEM), respectively. Binding and release of oxygen were measured using a Hemeox analyzer. Results Using the established Bthin-film rehydration^and Bdirect hydration^methods, Mb was found to be largely surface-associated with negligible aqueous encapsulation within polymersome suspensions. Through iterative optimization, a novel Bprogressive saturation^technique was developed that greatly increased the final concentrations of Mb (from<0.5 to>2.0 mg/mL in solution), the final weight ratio of Mb-to-polymer that could be reproducibly obtained (from<1 to>4 w/w% Mb/polymer), as well as the overall efficiency of Mb encapsulation (from<5 to>90%). Stable vesicle morphologies were verified by cryo-TEM; the suspensions also displayed no signs of aggregate formation for>2 weeks as assessed by DLS. BProgressive saturation^was further utilized for the encapsulation of a variety of other proteins, ranging in size from 17 to 450 kDa. Conclusions Compared to established vesicle formation methods, Bprogressive saturation^increases the quantities of functional proteins that may be encapsulated in nanoscale polymersomes.
INTRODUCTION
Proteins have recently shown outstanding pharmaceutical potential due to their ability to overcome significant limitations associated with traditional small molecule therapies [1, 2] . When compared to the interaction of a small-molecule with its biological target, protein therapeutics have higher folding energies (typically~7-20 kcal/mol) that allow for the adoption of larger and more precise three-dimensional configurations, which are often required for efficient binding and/or control of complex biological function [3] . As such, proteins can achieve superior binding selectivity and more potent ontarget activity. Currently, the modest number of macromolecular therapies in use, including the~200 protein drugs available worldwide, has demonstrated the remarkable potential of functional proteins as new leads in drug development [4] [5] [6] . Nevertheless, several barriers have hindered the ready development of macromolecules as human therapeutics, including: (i) the difficulty and/or expense of commercial scale production; (ii) biochemical instability that occurs in pathophysiologic environments or with prolonged storage; (iii) short circulatory half-lives; (iv) large steric hindrance that prevents effective tissue penetration; and, (v) risks associated with their potential to promote severe adverse effects, such as immunologic and anaphylactic reactions [5] .
To overcome some of these limitations, most pharmaceutical compounds either employ biocompatible polymers (e.g., poly(ethylene glycol) (PEG) or hyaluronic acid) or liposomes (i.e., lipid based vesicles) for protein complexation and in vivo delivery. A vast and expanding body of literature, however, has demonstrated that synthetic nanoparticles exhibit superior properties and can enhance drug delivery as compared to these more conventional formulations, which are limited by incomplete PEGylation and/or unstable encapsulation. Among the classes of nanoparticle vehicles, polymersomes, or self-assembled polymer vesicles comprised of amphiphilic block copolymers [7] [8] [9] [10] [11] [12] , are an emerging nanoscale delivery platform. Possessing thick polymeric membranes, polymersomes enable: (i) facile and stable loading of diverse therapeutic payloads through non-covalent interactions; (ii) improved mechanical stability that is 5-50 greater than that of liposomes or micellar structures constructed from similar molecular weight copolymers; (iii) a rich diversity in biochemical properties, which are imparted by their construction from a variety of copolymer compositions and which include: fully PEGylated surfaces and tunable in vivo circulation times, sitespecific targeting, environmental responsiveness, as well as complete biodegradation; and, (iv) economic and large scale production that obviates the need for costly postmanufacturing purification [7, 9, 11, [13] [14] [15] .
While the incorporation of proteins in long-circulating nanoparticles may enhance their pharmacologic performance and improve their on-target activity, most encapsulation efforts have utilized electrostatic interactions to incorporate a handful of highly anionic proteins [16] ; others have relied on chemical or genetic modification of the original protein for efficient and reproducible nanoparticle formation [17] [18] [19] [20] [21] . A major unaddressed challenge, however, is to establish and validate a generalizable method for the incorporation of large quantities of native protein in neutrally charged and/or fully PEGylated nanoparticles, which could be employed to prevent protein deactivation, improve circulatory half-life, achieve tissue localization, and minimize systemic activity [22] . Most nanoparticle fabrication techniques also involve the input of thermal, electric, ultrasonic or mechanical energy for particle formation [8, [23] [24] [25] ; alternative methods use organic co-solvents [26, 27] . In most cases, these fabrication protocols damage the structure and/or function of the protein, making nanoparticle encapsulation more challenging and obviating its utility [28] .
In the case of polymersomes, several methods have been developed for protein encapsulation, including: 1) rehydration of dry polymer (e.g., the Bthin-film rehydration^technique) [11, [29] [30] [31] or the extrusion of preformed vesicles (e.g., by Bhollow-fiber extrusion^) in the presence of protein solution [32] ; 2) Bdirect hydration^ [22, 33] ; and, 3) Belectroporation [ 34, 35] . Adopted from the liposome literature and widely employed for the encapsulation of organic small molecules, these methods result in low yields of polymersomeencapsulated protein (e.g., Bthin-film rehydration^), are limited to small-scale preparations (< 1 mL; e.g., Bdirect hydration^), and/or are best employed for application with a small number of highly charged proteins (e.g., those amenable to vesicle encapsulation by Belectroporation^). While the Bhollow-fiber extrusion^technique has been used for largescale preparations of liposome-encapsulated protein [32] , the elevated temperatures and/or pressures required for polymersome formation have limited its widespread applicability.
Here, we sought to perform a comparative and quantitative study to establish a generalizable method for producing scalable quantities of neutrally charged, fully PEGylated, and nanoscale polymersomes that encapsulate functional proteins. We first examined differences in small molecule and protein encapsulation by employing two related and extensively utilized polymersomes formulations, which were both comprised of diblock copolymers of poly(ethylene oxide)-block-poly(1,2 butadiene) (PEO-b-PBD) but that differed with respect to molecular weight and, ultimately, vesicle membrane thickness (i.e., OB18 and OB2-9) (Table I ; [36, 37] ). Methylene blue (mBlue; Mw=319.85 g/mol) was used as a model small molecule and myoglobin (Mb; Mw=17,600 Da) as a model protein with unique biological function (i.e., oxygen storage and release) (Scheme 1a). Two conventional vesicle formation techniques were preferentially employed for the incorporation of these water-soluble agents within PEO-b-PBD polymersomes: Bthin-film rehydration^and Bdirect-hydration^(Scheme 1b and c); a third-technique (Belectroporation^) produced uniformly poor results and was excluded from further comparisons (Scheme S1, Supplemental Information).
We compared the encapsulation of mBlue and Mb in PEOb-PBD polymersomes, which were generated by each of these various methods, in order to examine differences in the fidelity of small molecule versus protein encapsulation. We also monitored the concentrations and redox states of iron in the heme group of Mb (by inductively coupled plasma optical emission spectroscopy (ICP-OES) and by ultraviolet-visible (UV-Vis) absorption spectroscopy, respectively) in order to verify the encapsulation of intact protein by independent methods; the functional capabilities of encapsulated Mb to bind and release oxygen were measured using a Hemox analyzer. Finally, we describe the development of a highly reproducible and scalable Bprogressive saturation^technique for the efficient generation of polymersome-encapsulated Mb (PEM) suspensions. The generalizability of this method is further established by utilizing a variety of different proteins, ranging in size from 17 to 450 kDa.
MATERIALS AND METHODS

Materials
PEO(3900)-b-PBD(6500) (OB18) and PEO(1300)-b-PBD(2500) (OB29) were purchased from Polymer Source (Dorval, Quebec, Canada; Table I ). Horse skeletal muscle Mb, bovine blood hemoglobin (Hb), bovine serum albumin (BSA), catalase (C), fibrinogen (F), sodium hydrosulfite, poly(ethylene glycol) dimethyl ether (PEG500; Mw=~500 Da), protease from Streptomyces griseus (Bpronase^), and dichloromethane (DCM) were purchased from Sigma-Aldrich (St. Louis, USA). Horse spleen apoferritin (aFr) was purchased from Alfa Aesar (Ward Hill, USA). Immunoglobulin G (IgG) was purchased from LEE Biosolutions (St. Louis, USA). Dialysis tubing and vials were purchased from Spectrum Laboratories (Rancho Dominguez, USA). Sodium chloride, potassium chloride, sodium phosphate dibasic, potassium phosphate monobasic, mBlue, and Triton X-100 were purchased from Fisher Scientific (Suwanee, USA). All chemicals were of reagent grade unless otherwise stated.
A 1510 Bransonic® ultrasonic bath sonicator with a maximal energy of 70 watts was utilized for all sonication procedures (Bransonic Ultrasonics, Danbury, USA). Electroporation was performed using a Gene Pulser® (Bio-Rad, Hercultes, CA, USA). Particle sizes were measured using Delsa TM Nano, a dynamic light scattering (DLS) instrument (Beckman Coulter, Indianapolis, USA). Mb and mBlue concentrations were determined by absorption spectroscopy using a Genesys TM 10S UV-Vis spectrophotometer (Thermo Scientific, Suwanee, USA). The concentrations of proteins in polymersome suspensions were further measured with a BCA Protein Assay Kit, utilizing UV-Vis spectrophotometry and by following the manufacturer's protocols (Pierce Biotechnology, Inc; Rockford, USA). Iron concentrations in polymersome-encapsulated Mb suspensions were determined using a Vista-PRO TM CCD ICP-OES (Varian, USA). Oxygen equilibrium binding was studied using a Hemox TM -Analyzer (TCS Scientific Corp, New Hope, USA).
BThin-Film Rehydration^Method
10 mg of OB18 polymer was dissolved in 200 μL of DCM. The polymer solution was deposited on Teflon wafers (15×15 mm) that were subsequently dried for 30 min at room temperature (RT). The films were further kept under vacuum overnight at , and 60°C. The samples were then sonicated for 30 min at RT followed by dialysis for 40 h at 4°C (MW cutoff=1000 kDa). The dialysis buffer was exchanged with 1 Liter of fresh buffer every 7-8 h; free mBlue or Mb solutions were also subject to dialysis and served as controls to verify their full removal in the dialysate under these conditions. Quantification of mBlue and Mb encapsulation in polymersomes was determined vida infra (see BQuantification of mBlue/Mb^).
BDirect Hydration^Method
The Bdirect hydration^method was adopted from O'Neil et al. with minor modification [22] . In brief, the protocol consisted of 4 steps: 1) addition of 10 mg of OB18 to 10 mg of PEG500 in a 1.5 mL centrifuge tube followed by heating for 20 min at 95°C; 2) mixing by vortexing and cooling to RT followed by the addition of 10 μL of mBlue (21 mg/mL) or Mb solution (150 mg/mL) in PBS (10 mM, pH 7.4); 3) diluting with 20, 70, and 900 μL of PBS with mixing after each step (via vortexing); and 4) dialysis for 30 h at RT or at 4°C (MW cutoff = 1000 kDa) to remove unencapsulated mBlue or Mb, respectively. The dialysis buffer was exchanged with 1 Liter of fresh buffer every 7-8 h. Quantification of mBlue and Mb encapsulation in polymersomes suspensions was determined vida infra. As control experiments, free mBlue and Mb suspensions were also subject to similar dialysis conditions; UV-Vis spectroscopy of both the dialysate and retained solution at the completion of the dialysis experiment demonstrated no retention of unencapsulated agent by the dialysis membrane.
Quantification of mBlue/Mb
The amounts of mBlue or Mb that were encapsulated in dialyzed polymersome suspensions were determined by measuring the solution absorbance at 665 nm (mBlue) or at 410 nm (Mb), using a UV-Vis spectrophotometer. In brief, calibration curves for mBlue and Mb were developed using serial dilutions of known concentrations. Before UV-Vis measurements were conducted, polymersome-encapsulated mBlue or Mb samples were diluted with a 10-fold excess volume of THF or 1% triton, respectively. This step was necessary to destroy the vesicles and to release the encapsulated mBlue or Mb, thereby reducing light scattering during UVVis measurements that would otherwise ensue due to intact particles. The UV-Vis spectra were also baseline corrected to obtain the peak absorbance of mBlue or Mb in solution. The samples concentration of mBlue or Mb in the dialysis controls were similarly subtracted from the concentration of the mBlue or Mb in the destroyed polymersome samples to obtain the absolute concentration of each agent in the original polymersome suspension. To measure the iron content in PEM suspensions (as a corroboration of Mb concentration in that sample), 5-10% (v/v) of Triton X-100 was added; the mixture was digested by heating in aqua regia for 3 h at 98°C and the sample was subsequently diluted with deionized water. ICP-OES measurements were then conducted and the iron content in the experimental samples was determined by comparison to the standard calibration curve. For each experimental sample, the concentrations of Mb (as calculated by UV-Vis) were compared to those obtained via ICP-OES and via the BCA assay, which was also conducted by utilizing UV-Vis spectrophotometry and by following the manufacturer's protocols (Pierce Biotechnology, Inc; Rockford, USA). Loading of aqueous encapsulants in polymersomes was quantified and expressed as the final weight percentages of encapsulant-to-polymer that comprised the vesicles in suspension (e.g., w/w% Mb/polymer).
Quantification of metMb
The amount of metmyoglobin (metMb, i.e., oxidized Mb with an Fe(III)-heme group) in polymersome suspensions was quantified using a modified UV-Vis absorption protocol that was previously established for the measurement of cyanomethemoglobin [38] [39] [40] [41] [42] [43] . In brief, the absorbance of Mb was measured at 630 nm (L 1 ) against a blank reference (deionized water). One drop of KCN solution (1 part 10% KCN and 1 part 50 mM phosphate, pH 7.6) was added and mixed with the treated Mb samples. This reaction step was necessary to convert metMb to cyanometmyoglobin (cyanoMb), which does not absorb at 630 nm. After 2 min, the absorbance was measured at 630 nm (L 2 ); the absorbance of deionized water served as the blank reference. The concentration of metMb was determined using Eq. 1:
where E=3.7 (cm×mM) −1 and is the extinction coefficient of metMb at 630 nm; D 1 is the dilution factor in this experiment (cuvette length = 1 cm as denoted in the equation).
To determine the concentration of Mb, one drop of 20% K 3 (Fe(CN) 6 ) was added and mixed with the treated Mb sample. The solution was allowed to react for 2 min and an additional drop of 10% KCN was added. The absorbance of the sample was then measured at 540 nm (L3). The concentration of total Mb was determined using Eq. 2:
where E=11.3 (cm×mM) −1 and is the extinction coefficient for cyanoMb at 540 nm; D 2 is the dilution factor (cuvette length=1 cm as denoted in the equation).
The percentage of metMb in the original solution was determined using Eq. 3:
Structural Characterization of Polymersomes
Polymersome suspensions were diluted in PBS solution and their hydrodynamic diameters were measured by DLS using a standard 1.5 mL semi-micro Plastibrand polystyrene cuvette (VWR, Atlanta, USA). The morphologies of blank polymersomes and PEM were visualized by cryo-TEM (JEOL 2100 F, USA). In brief, polymersome samples were suspended in a microperforated grid, rapidly vitrified using liquid ethane (−183°C), and loaded onto a cryogenic sample holder for cryo-TEM imaging at 200 kV.
Optimization of Various Steps in the Direct Hydration Protocol
Modifications to each of the 4 steps in the original Bdirection hydration^protocol were conducted and summarized below (see also Table II ).
Modification of
Step 1: Effects of Different Mb Oxidation States (i.e., Using an Organic Solvent vs. Heat)
Following the Bdirect hydration^protocol (vide supra), 10 mg of OB18 and 10 mg of PEG500 were blended either by: A) mixing by dissolution in DCM (50 μL), or B) heating to 95°C for 1 h followed by cooling to room temperature. Samples in DCM were further subject to drying under vacuum at RT (overnight) to ensure removal of all organic solvent prior to the addition of aqueous protein solution. In the case of heating, the samples were subject to heating at 95°C for 1 h (instead of only 20 min as utilized in the original Bdirect hydration^protocol) to further ensure maximal polymer mixing. In all cases, Mb concentrations in the final suspensions were determined by UV-Vis, ICP-OES and compared.
Step 2: Effects of Different Mb Oxidation States (i.e., Utilizing metMb vs. Oxymyoglobin)
The Bdirect hydration protocol^(vide supra) was modified to expose the initial mixture of polymer and PEG500 to 1 h (instead of 20 min) of heating at 95°C. The effect of the oxidation state of iron in the heme group of Mb on the efficiency of polymersome encapsulation was studied by using metMb vs. oxymyoglobin (oxyMb; i.e., Fe(II)Mb) for polymersome encapsulation. MetMb solution was first prepared by dissolving lyophilized Mb in PBS; the same solution was treated with 1 wt% Na 2 S 2 O 4 to obtain the reduced Mb form (oxyMb). Mb concentrations, weight percentages of Mbto-polymer, and the final efficiencies of polymersome encapsulation of Mb, using either metMb vs. oxyMb in the protocol, were measured by UV-Vis, ICP-OES and compared.
Modification of Step 2: Effects of Sonication and Temperature on the Oxidation State of Mb
Lyophilized Mb was dissolved in PBS (at 150 mg/mL) and reduced with Na 2 S 2 O 4 to obtain an oxyMb solution that was further subjected to various environmental conditions, including heating to either 40 or 50°C (with or without sonication) for 2-5 h. The extent of Mb oxidation was determined by measuring the percentages of metMb in the total polymersome-encapsulated (oxy)Mb suspensions, using the cyanoMb method (vide supra). Step ( 
Modification of Step 3: Effects of Different Sonication Times on Mb Encapsulation
Following the Bdirect hydration protocol^(vide supra), upon addition of PEG500 to OB18 polymer, the sample was heated, mixed by vortexing, cooled to RT, and 10 μL of Mb solution (150 mg/mL) in PBS (10 mM, pH 7.4) were added. The sample was then further combined with 10, 20, 50, and, finally, 100 μL of PBS, followed by sonication for either: A) 0 min, B) 15 min, C) 30 min, D) 45 min, or E) 60 min after each dilution step. All samples were then dialyzed for 40 h at 4°C (MW cutoff=1000 kDa). The final Mb concentrations, weight percentages of Mb-to-polymer, and the efficiencies of polymersome encapsulation of Mb were measured by UVVis, ICP-OES and compared.
Modification of Step 4: Effects of Proteolysis to Distinguish non-Specifically Bound vs. Encapsulated Protein in the Final Polymersome Suspensions
PEM suspensions were generated by the Bdirect hydrationm ethod (vide supra), using OB18 polymer and oxyMb solution (150 mg/mL) with subsequent dialysis at 4°C for at least 40 h (MW cutoff=1000 kDa). The samples were then treated with 0.4 wt% pronase solution for 1, 2, 3, 6, 12, 18, or 24 h at RT and again dialyzed overnight at 4°C. Free oxyMb solutions were also subjected to similar pronase treatment in order to serve as a positive control (for the rate and extent of proteolysis). Mb encapsulation in polymersomes (before and after proteolysis) was measured by UV-Vis, ICP-OES and compared.
Improvement of Mb Encapsulation Efficiency (%Mb EE)
Following the Bdirect hydration^protocol, 10 mg polymer and 10 mg of PEG500 were initially heated in a 1.5 mL microcentrifuge tube for 1 h at 95°C and subsequently cooled to RT. Different volumes of: A) pure PBS, or B) 5 different Mb solutions (varying in concentration from 8 to 150 mg/mL oxyMb in PBS) were then combined with this mixture in 5 addition steps: i.e., 10, 10, 20, 50, and, finally, 100 μL of solution were added to the polymer mixture. When introducing additional amounts of Mb to the polymer mixture, the final (v/v) ratio of Mb to PBS (i.e., BMb:PBS^) used in each of the 5 addition steps were 10:180 (i.e., 8 mg/mL Mb), 20:170 (i.e., 15 mg/mL Mb), 40:150 (i.e., 31 mg/mL Mb), 90:100 (i.e., 71 mg/mL Mb), and 190:0 (i.e., 150 mg/ mL Mb). The samples were then proteolyzed using 0.4 wt% pronase and again dialyzed overnight at 4°C (MW cutoff= 1000 kDa). Mb encapsulation was measured using UV-Vis spectrophotometry. Mb encapsulation efficiencies were calculated using Eq. 4:
Where v 1 =initial volume of the unencapsulated Mb (mL); c 1 = initial concentration of unencapsulated Mb (mg/mL); v 2 =volume of polymersome-encapsulated Mb obtained after dialysis and proteolysis (mL); c 2 =concen-tration of encapsulated Mb obtained after dialysis and proteolysis (mg/mL).
Development of the BProgressive SaturationT echnique
In combining the various experimental conditions that yielded the most favorable results in each of the comparative experiments (vide supra), a Bprogressive saturation^technique was developed that optimized the generation of polymersomeencapsulated protein suspensions. In brief, 10 mg of polymer and 10 mg of PEG500 were heated to 95°C for 1 h. The mixture was then centrifuged and cooled to RT. Lyophilized Mb was dissolved in PBS, reduced with Na 2 S 2 O 4 (1 wt%) to generate an oxyMb solution (at 150 mg/mL in PBS), and used for stepwise addition to the polymer mixture: 10, 10, 20, 50 and 100 μL of oxyMb solution were introduced, followed by thorough mixing and sonication for 30 min at RT after each step. The samples were then sonicated for an additional 30 min at RT followed by dialysis at 4°C for at least 40 h (MW cutoff = 1000 kDa). The dialysate was exchanged with 1 liter of fresh buffer every 8-10 h and UV-Vis measurements of the dialysis control solution (e.g., free Mb solution subject to identical dialysis conditions) verified that all free protein was successfully removed. Surfaceassociated protein was further eliminated by proteolysis via treatment with 0.4 wt% pronase solution followed by a second overnight dialysis at 4°C (MW cutoff = 1000 kDa). Mb encapsulation (before and after proteolysis) in polymersome suspensions was determined via UV-Vis, ICP-OES and compared.
Stability of Polymersome-Encapsulated Protein Suspensions
PEM suspensions were prepared from OB18 polymer and oxyMb using the optimized Bprogressive saturation^tech-nique (vide supra). The samples were stored at 4, 23, and 37°C for 2 weeks. At predetermined time points, Mb concentrations were quantified using UV-Vis spectroscopy (vide supra); weights of polymer were measured after lyophilization; and, particle sizes were determined by DLS for PEM suspensions subject to each condition.
Equilibrium Binding of Oxygen in Polymersome-Encapsulated Mb Suspensions
The equilibrium binding and dissociation curves for oxygen in suspensions of free Mb and PEM were obtained at 37°C using a Hemox TM -Analyzer. Samples were allowed to saturate to a pO 2 of 147 mmHg (using compressed air) and then deoxygenated (using a compressed nitrogen stream). The absorbance of oxygenated and deoxygenated free Mb and PEM suspensions were recorded as a function of pO 2 via dual wavelength spectroscopy. Oxygen equilibrium curves were fit to a four-parameter (A 0 , A ∞ , P 50 , n) Hill model (Eq. 5). In this model, A 0 and A ∞ represent the absorbance at 0 mmHg and at 147 mmHg, respectively. The pO 2 represents the partial pressure of oxygen; P 50 represents the partial pressure where the sample was 50% saturated with O 2 ; and, n represents the cooperativity coefficient for the sample.
Polymersome Encapsulation of Different Proteins Using the BProgressive Saturation^Technique
The generalizability of the Bprogressive saturation^technique was tested using proteins of varying sizes: i.e., Mb (17 kDa), hemoglobin (Hb; 64 kDa), bovine serum albumin (BSA; 66 kDa), immunoglobulin G (IgG: 150 kDa), catalase (250 kDa), fibrinogen (340 kDa), and apoferritin (450 kDa). Each protein was dissolved in PBS (10 mM, pH 7.4) at its maximal solubility, corresponding to final suspension concentrations of 150, 150, 40, 20, 50, 50, and 25 mg/mL, respectively. The Bprogressive saturation^protocol was followed to encapsulate these proteins in OB29 polymersomes. Free proteins were separated by dialysis for at least 40 h at 4°C (MW cutoff=1000 kDa). Surface-associated protein was removed by proteolysis via treatment with 0.4 wt% pronase solution followed by overnight dialysis at 4°C (MW cutoff = 1000 kDa). Protein encapsulation (before and after proteolysis) in polymersome suspensions was quantified via the BCA assay, utilizing UV-Vis spectrophotometry and by following the manufacturer's protocols (Pierce Biotechnology, Inc; Rockford, USA). The final concentrations of protein were divided by those of polymer and expressed as the final weight ratios of protein-to-polymer that comprised the polymersomes in suspension (i.e., w/w% Mb/polymer).
Statistical Analysis
Data are presented as the mean ± the standard deviation of the mean (SD). A minimum of three experimental replicates was used for each condition. One-way analysis of variance (ANOVA) was conducted using GraphPad software (San Diago, USA). A p value of<0.05 was considered statistically significant.
RESULTS
Encapsulation of mBlue and Mb in Polymersome Suspensions Using Conventional Methods
In order to establish a baseline for comparisons of small molecule and protein encapsulation in polymersome suspensions, the final concentrations, weight percentages (i.e., weight of encapsulated agent compared to the weight of the polymer that comprised the vesicle), and the efficiencies of encapsulation for the small molecule mBlue were first determined with OB18-based polymersomes. Using the Bthin-film rehydration^method, no significant differences in mBlue encapsulation were observed in polymersomes formed at 40 vs. 60°C (e.g., the final polymersome composition consisted of 4.1 vs. 5.0 w/w% mBlue/polymer, respectively; Fig. 1a ). When thin-film rehydration was attempted at 23°C (room temperature), the encapsulation of mBlue was found to be negligible (results not shown), possibly due to the observation that the polymer films did not swell after 48-72 h of hydration; PEOb-PBD-based polymersomes require the input of energy for vesicle formation, which is usually supported by using elevated temperatures (e.g., > 45°C) [8, 44] . To improve the efficiency of encapsulation at lower temperatures, which would be necessary when employing labile proteins, encapsulation of mBlue was also studied by the Bdirect hydration^meth-od; the final weight ratio of mBlue-to-polymer in these polymersomes was, however, again found to be very low (~1.2 w/w% mBlue/polymer; Fig. 1b) . We next sought to compare the results obtained for mBlue encapsulation to those that could be achieved for Mb using the same polymersome formation techniques. Polymersomeencapsulated Mb (PEM) suspensions formed at 23°C by Bthin-film rehydration^were initially found to be comprised of~2.7 w/w% Mb/polymer. After the addition of a proteolysis step to remove any surface-associated Mb (i.e., free protein that was nonspecifically bound), the final composition of the polymersomes was found to be~0.5 w/w% Mb/polymer, indicating that only very small amounts of protein were being encapsulated within polymersomes via this method (Fig. 1c) . In order to improve the concentrations and the final weight percentages of Mb in PEM suspensions, polymersome generation at higher temperatures was again attempted (e.g., utilizing Bthin-film rehydration^at 40 and 60°C); these experiments, however, only resulted in protein denaturation and aggregation (results not shown). In contrast, PEM suspensions prepared by Bdirect hydration^at 23°C displayed good colloidal properties and the characteristic absorption spectra of intact Mb; the final loading ratio of Mb-to-polymer in these PEM suspensions, however, was again very low (i.e.,~0.3 and 0.1 w/w% Mb/polymer before and after proteolysis, respectively; Fig. 1d ). Thus, while Bthin-film rehydration^and Bdirect hydration^may be used to reproducibly encapsulate mBlue at reasonable efficiencies, their utility for Mb encapsulation was found to be uniformly poor.
Optimization of the BDirect Hydration^Protocol to Improve Protein Encapsulation
In order to develop an improved method for the generation of polymersome-encapsulated protein suspensions, the contributions of each of the various steps in the Bdirect hydrationp rotocol on the final concentrations, weight percentages, and encapsulation efficiencies of Mb in OB18-based polymersomes were systematically evaluated (Table II) . We sought to combine features of both the Bdirect hydrationâ nd Bthin-film rehydration^techniques in order to improve polymersome encapsulation of functional protein. As such, changes were implemented iteratively in order to optimize experimental conditions.
Step 1: Effects of Blending Technique (i.e., Dissolving Polymer in Organic Solvent vs. Adding Heat)
Improving polymer dissolution is critical to efficient encapsulation of protein. As such, we sought to first compare the effects of utilizing an organic solvent versus adding heat in order to blend OB18 with PEG500 homopolymer in the first step of the Bdirect hydration^protocol; we subsequently compared both strategies with respect to the final yield of polymersomes and, ultimately, to the concentrations and efficiencies of protein encapsulation that could be obtained by each method. If the two polymers were first mixed by dissolution in DCM (followed by polymersome formation after organic solvent evaporation), the final weight ratio of Mb-topolymer in PEM suspensions was~2 w/w% Mb/polymer. In comparison, initial heating of dry OB18 and PEG500 to 95°C for 1 h improved mixing and promoted more efficient polymersome generation, yielding a significantly higher weight ratio of Mb-to-polymer in the PEM suspensions (~5 w/w% Mb/polymer; Fig. 2a ) that corresponded to a greater amount of encapsulated protein.
Step 2: Effects of Different Mb Oxidation States (i.e., Utilizing metMb vs. oxyMb for Polymersome Encapsulation)
In addition to improving polymeric blending, Mb encapsulation in polymersomes was found to be further augmented when the starting Mb stock solution was first reduced with sodium dithionite to convert all metMb to the oxyMb form. OxyMb contains a central heme group with iron in the ferrous state (i.e., Fe(II)), which improves the solubility of the protein when compared to its metMb form that contains Fe(III). This oxyMb solution was further desalted via dialysis prior to utilization in the initial addition step of the Bdirect hydrationp rotocol, which was found to be necessary to increase the loading of Mb in PEM suspensions (i.e., the final weight ratio of Mb-to-polymer). When oxyMb was used in the initial protocol step, PEM suspensions comprised of~6 w/w% Mb/polymer were formed, which was a statistically significant improvement over the 4 w/w% Mb/polymer that could be obtained if metMb was utilized instead (Fig. 2b) .
Step 2: Effects of Sonication and Temperature on Mb Oxidation
More than 40% of the oxyMb that was used in the initial step for polymersome encapsulation was found to be reoxidized to metMb within 2 h of heating at 50°C; by contrast, only~15% metMb was generated from the initial oxyMb solution if lower temperatures were employed for polymersome formation (e.g., heating for 2 h at 40°C). The rate of Mb oxidation at 50°C was also significantly higher than that observed at 40°C, regardless of the addition of sonication or the power that was utilized (Fig. 2c) . As such, it was determined that sonication a b c d had no effect on Mb oxidation; and, it was, thus, preferentially employed to both promote polymer mixing and to provide interfacial energy to augment polymersome formation.
Step
3: Effects of Sonication on Improving the Encapsulation of Mb in Polymersomes
Despite improvements in polymer blending that could be afforded by heating the polymer and PEG500 solution in the first step of the Bdirect hydration protocol^, as well as increases in the yield of PEM afforded by utilizing oxyMb for polymersome encapsulation, the final weight ratios of Mb-to-polymer were again found to be very low after pronase treatment (~0.2 w/w% Mb/polymer); this would indicate that most of the Mb was only surface associated as opposed to encapsulated within the vesicle suspensions. The encapsulation efficiency, however, could be increased by >30× if the samples were sonicated for 30 min at RT after each dilution step (i.e., sonicating after introducing additional volumes of aqueous solution to dilute the concentrations of polymer in suspension). As seen from the results depicted in Fig. 2d , the relative amounts of Mb in PEM suspensions could be increased to~5.5 w/w% Mb/polymer, supporting the addition of this sonication step to the original Bdirect hydration^protocol.
Step 4 surface-associated (i.e., non-specifically bound) Mb. It was observed that all free protein in solution, which was utilized as a positive control for proteolysis, and all surface-associated Mb in PEM suspensions were digested in 2 h; neither increasing pronase exposure time nor concentration further augmented Mb removal. These results would indicate that only encapsulated Mb was thereafter retained (Fig. 2e) .
Optimization of Mb Encapsulation Efficiency
Five sets of experiments were done with various Mb-to-PBS volume ratios (Mb:PBS) in order to establish the optimal Mb concentration to use in each subsequent addition step in our modification of the original Bdirect hydration^protocol. Notably, when Mb:PBS increased, the final w/w% Mb/polymer in the PEM suspensions also increased; but, the Mb encapsulation efficiency (%Mb EE) decreased as a result. In other words, the final Mb-to-polymer mass ratio was maximized when all addition steps were conducted using a maximally concentrated Mb solution (i.e., Mb:PBS=190:0, corresponding to 150 mg/mL oxyMb) (Fig. 2f) . %Mb EE (as defined in Materials and Methods), however, was largest when Mb:PBS was minimal (i.e., 10:180). As the amount of protein in the final polymersome suspension is ultimately the metric that must be optimized for therapeutic administration (in order to minimize the amount of associated carrier that is introduced to a subject), it was determined that a pure Mb solution (i.e., 150 mg oxyMb/mL) would be used for each addition step in the ultimate encapsulation protocol, maximizing the final loading of myoglobin in PEM suspensions (i.e., w/w% Mb/ polymer).
Maximizing Protein Encapsulation
Through BProgressive SaturationB y incorporating each of the aforementioned steps, an optimized Bprogressive saturation^technique was established that improved upon the results of the original Bdirect hydrationm ethod (Scheme 1d). Following the Bprogressive saturationp rotocol, the final content of Mb in OB-18-based PEM suspensions was found to be 6.1 and 3.2 w/w% Mb/polymer before and after proteolysis, respectively. Quantification of the iron content (and hence the numbers of intact heme groups in each of the polymersome suspensions) by ICP-OES corroborated UV-Vis measurements of protein concentration; the final compositions of PEM were found to be 7.9 and 5.1 w/w% Mb/polymer before and after proteolysis, respectively (Table III) . Notably, the percentage of metMb (with respect to the total Mb content in these suspensions) was determined by UV-Vis spectrophotometry and found to be~8 and 6% in non-proteolyzed (PEM-SE) and proteolyzed (PEM-E) samples, respectively (Table III) .
Polymersome Encapsulation Using Block Copolymers and Proteins of Varying Molecular Weight
The Bprogressive saturation^technique was also utilized to encapsulate Mb in a second PEO-b-PBD-based polymersome system comprised of the OB29 diblock copolymer. When compared to OB18, OB29 has a smaller molecular weight (Mw = 3800 g/mol vs. 10400 g/mol) and generates polymersomes with a shorter PEG brush border (1.3 vs. 3.9 kDa), thinner bilayer membrane (9.6 nm vs. 14.8 nm), and smaller average hydrodynamic diameter (130 vs. 200 nm) (Table I) [36, 37] . When compared to the initial experiments with OB18, similar encapsulation results were obtained with Mb in OB29-based polymersomes (Table IV) . The generalizability of the Bprogressive saturation^technique was further established when analogous results were obtained with several larger proteins, including hemoglobin (Hb; 64 kDa), bovine serum albumin (BSA; 66 kDa), immunoglobulin G (IgG: 150 kDa), catalase (250 kDa), fibrinogen (340 kDa), and apoferritin (450 kDa) ( Table IV) .
Characterization of PEM Suspensions
The size distributions of the final OB18-and OB29-based PEM suspensions were measured by both DLS (Fig. 3a) and by cryo-TEM (Fig. 3b and c) . These results confirmed a mean particle diameter of approximately 200 and 130 nm for OB18 vs. OB29-based polymersomes, respectively. The stability of the OB18-based PEM suspensions were further examined over 2 weeks and at three different temperatures (i.e., 4, 23, and 37°C); the particles demonstrated no aggregation as evidence by their consistent particle numbers and stable size distributions in suspension (Fig. 3d) . The extent of Mb encapsulation in these PEM suspensions was also found to be unaffected after 2 weeks of exposure to these three different temperatures (Fig. 3e) . Finally, the functional status of PEM (i.e., retention of the ability of Mb to bind and release oxygen) was verified by dual wavelength spectroscopy (Fig. 3f) . The oxygen equilibrium curve of PEM after proteolysis (PEM-E) was similar to that of free Mb but demonstrated a slight hyperbolic shape at lower oxygen tensions, indicating the encapsulation of functional protein but with subtle changes in oxygen binding and release; the P 50 (i.e., the partial pressure that corresponded to 50% saturation with O 2 ) and n (the cooperativity coefficient) for PEM-E were also larger than that of free Mb (Table V) . The oxygen equilibrium curve and the values of P 50 and n for PEM before proteolysis (PEM-SE) were intermediate between those of free Mb and PEM-E, supporting the incorporation of both surface-associated and encapsulated Mb in these suspensions.
DISCUSSION
While lipid-based vesicles (i.e., liposomes) have been extensively utilized in biomedical research, examples of their widespread clinical adoption are few. These translational shortcomings may be attributable to material limitations inherent to phospholipid-based drug delivery vehicles, including compromised suspension stability, premature drug release, and limited product shelf-life. In contrast, polymersomes are formed from higher molecular weight amphiphilic block copolymers that impart a broad and tunable range of carrier properties. To date, a generalized method for the efficient and reproducible encapsulation of functional proteins in neutrally charged, fully PEGylated, and nanoscale polymer vesicles has not, however, been established. While adoption of various liposome encapsulation techniques has enabled facile incorporation of small molecules within polymersomes, these methods cannot directly be applied for scalable encapsulation of functional proteins. Often, there is a trade-off in the maximal concentration of aqueous protein that may be encapsulated (i.e., mg protein/mL solution), the final loading ratio of protein-to-polymer that comprises the polymersome structure (i.e., w/w% protein/polymer), and/or the protein encapsulation efficiency (i.e., the percentage of the initial protein suspension that is retained). Further, the value of each of these parameters often varies upon experimental run and is highly dependent on the nature of the protein, the exact block copolymer formulation, and the encapsulation method that is utilized (Table VI) . Here, we have performed a comparative and quantitative study of several conventional liposome encapsulation techniques in order to generate an optimized and reproducible method to improve the encapsulation of functional proteins in nanoscale polymer vesicles. PEO-b-PBD copolymers were used to form polymersomes that possessed fully PEGylated surfaces, that were uncharged, and that were nondegradable; thus, they were an ideal system for ensuring vesicle integrity and minimizing unwanted protein interactions or modifications. Two different molecular weight PEO-b-PBD polymers (i.e., OB18 and OB29) were further employed to determine the generalizability of the results as they pertain to polymersomes of different PEG lengths, membrane core thicknesses, and minimal sizes. Methylene blue (mBlue; Mw=319.85 g/mol) was first used as a model small molecule in order to establish the baseline encapsulation parameters (i.e., aqueous suspension concentrations, final weight percentages, and encapsulation efficiencies) that could be obtained by each method. mBlue is highly stable in aqueous suspension and has a strong near-infrared absorbance that enables ready spectrophotometric detection; it was thus employed to confirm the fidelity of the results in reference to previously published studies that examined the encapsulation of other organic small molecules. Mb was used as a model protein for polymersome encapsulation as it possesses a size (Mw=17,600 Da) and thermal stability (denaturation above 60°C) that is comparable to other small proteins with therapeutic potential; Mb also has a strong UVVis absorbance that enables ready identification of its functional status (as determined by the redox state of its Fe-containing heme group, which mediates its oxygen binding capabilities). Mb has additionally been used in other investigations and its employment in this study enabled ready comparisons of our results (Table IV) to baseline values from the literature (Table VI) . mBlue was easily encapsulated in PEO-b-PBD polymersomes formed by Bthin-film rehydration^(at elevated temperatures), yielding final weight ratios of mBlue-topolymer of 4.1 and 5.0 w/w% when formed at 40 and 60°C, respectively; for Mb encapsulation, however, similar conditions only led to protein degradation. Notably, when vesicles are formed by Bthin-film rehydration^, hydrophilic lamellae (a.k.a. sponge-like structures) are first formed [22, 49] ; this is followed by transformation into hexagonally packed vesicles and finally into fully dispersed polymersomes [22, 49, 50] . When Bthin-film rehydration^is attempted in solutions of soluble small molecules (or proteins), these water-soluble species adsorb to the surfaces of the budding lamellae, which subsequently adopt a spontaneous (or preferred) curvature. During formation, these membranes preferentially bend away from the aqueous compartment that contains the higher concentration of adsorbing species, thereby excluding the water-soluble agents from vesicle encapsulation [49] . Ultimately, the input of energy can overcome this spontaneous surface tension in order to promote vesicle encapsulation. The amount of energy that is required scales with the size of the adsorbed molecule and the membrane thickness of the vesicle [36, 37, 51, 52] . Thus, while it is easy to disrupt liposomes and enable effective small molecule and protein loading by Bthin-film rehydration^, the input of thermal (and/or sonic) energy only enables effective encapsulation of small molecules in polymersome suspensions.
The Bdirect hydration^method, by contrast, was developed as a hybrid of two other preparation methods, namely Bsolvent dispersion^and Bhomopolymer addition^ [22] . In the Bdirect hydration^protocol, the hydrophilic polymer PEG500 is used to disrupt the interactions of hydrophobic chains [22] . With subsequent additions of aqueous solution, self-assembly of vesicles from budding lamellae that have dispersed protein is promoted and results in improvements in aqueous encapsulation; encapsulation efficiencies as high as 37% have been observed [22] . Supporting these initial studies, we generated PEM suspensions by Bdirect hydration^at 23°C and measured protein encapsulation efficiencies of >10%; the encapsulated Mb exhibited good suspension properties and the characteristic absorption spectra of the intact protein.
The final loading of Mb in these PEM suspensions, however, was found to be very low (~0.3 w/w% Mb/polymer), which was consistent with results calculated from the original paper (Table VI) [22] . Upon addition of a protease solution to induce proteolysis of all surface-associated (i.e., non-specifically bound) protein, the final Mb composition in PEM suspensions was found to be even lower (< 0.1 w/w% Mb/polymer). As the loading of therapeutic proteins within the aqueous cavities of polymersomes is ultimately the metric that must be maximized for translational applications (in order to minimize the amount of associated carrier that is introduced to a subject), it was evident that the development of a more robust encapsulation protocol was required. By optimizing and combining various steps from multiple vesicle formation methods, a new Bprogressive saturationt echnique was developed that enabled efficient encapsulation of functional proteins within polymersomes. Factors influencing the final concentration of protein, the relative loading level that could be achieved within the carrier (i.e., w/w% protein/ polymer), and the efficiency of protein encapsulation were systematically evaluated using Mb as a model protein and OB18 as the polymersome system. We found that factors such as the molecular weight of the polymer, the oxidation state and concentration of the protein, the pH and nature of the buffered solution, the exact polymer hydration conditions (i.e., time, temperature, and blending technique), and the number and duration of sonication steps all had effects on the concentration and the fidelity of the final polymersome-encapsulated protein product. For the optimized Bprogressive saturationp rotocol, 5 subsequent additions of Mb solution were made to the PEG/polymer mixture, in lieu of serial dilutions with PBS (as described in the original Bdirect hydration^paper [22] ). The significant improvements in the final Mb-to-polymer weight ratios that were obtained (i.e., 4-6 w/w% Mb:polymer with Bprogressive saturation^vs. 0.1-0.3 w/w% by Bdirect hydration^) suggest that the polymersome formation process is not complete during the initial addition step; further encapsulation is accomplished with each subsequent introduction of protein solution.
Notably, we found that there was a direct tradeoff between Mb encapsulation efficiency and the final weight ratios of Mbto-polymer that could be achieved based on the concentrations of free Mb that were used for each addition step. While other studies have reported achieving both high encapsulation efficiencies and large loading capacities (i.e., high final weight ratios of Mb-to-polymer), it is important to underscore that these investigations did not attempt to differentiate the extent of surface-associated vs. encapsulated protein in the final vesicle suspensions. Aqueous encapsulation of protein is, of course, preferred in order to assure that the final product meets the original objectives for utilizing a polymersome delivery vehicle: i.e., to avoid biochemical instability, to increase circulatory half-life, to minimize adverse side effects, and to achieve controlled release of the associated protein. Larger scale batches of PEM, which were generated from 500 mg of polymer using the Bprogressive saturation^method, yielded similar encapsulation results to those obtained with these small-scale batch preparations, supporting the scalability of the technique. Moreover, by employing different proteins that varied over a large range of molecular weights and sizes, including those associated with therapeutically relevant antibodies and enzymes, the robustness and the versatility of the Bprogressive saturation^method were established.
Using nondegradable PEO-b-PBD-based polymersomes as a model system, we demonstrated the colloidal stability of PEM suspensions at 4, 23, and 37°C for over 2 weeks; the oxygen binding and release capabilities of Mb in these polymersome suspensions were further examined and verified to be preserved. Notably, the oxygen equilibrium curve of PEM demonstrated a slight hyperbolic shape at low oxygen tensions as compared to that of free Mb; parametric fitting also demonstrated a larger P 50 and n (cooperativity coefficient) for PEM as compared to the unencapsulated protein. Together, these results indicate a slight reduction in oxygen binding affinity but also a mild decrease in the off-loading of oxygen at low oxygen tensions for PEM as compared to free Mb. Mechanistically this may be mediated by decreased oxygen transport across the thick polymersome membrane. Notably, the P 50 and n of polymersome suspensions that contained both surface-associated and encapsulated Mb (PEM-SE) were of intermediate values to those of free Mb and pure polymersome-encapsulated Mb (PEM-E) obtained by proteolysis of all surface-associated protein. The explanation that membrane transport affects are most likely determining changes in oxygen binding is further supported by the results of kinetic studies that measured the oxygen binding and release of hemoglobin (Hb) in polymersomes [53] ; they observed a decrease in the rate of O 2 offloading in polymersomeencapsulated Hb suspensions, in RBCs, as well as with PEGconjugated liposome-encapsulated Hb (LEH) as compared to acellular (free) Hb.
CONCLUSIONS
Conventional vesicle formation methods may be used to encapsulate small molecules within polymersomes (as demonstrated in this study using mblue); but, they do not yield consistent, reproducible, or scalable encapsulation of functional proteins in neutrally charged, fully PEGylated and nanoscale polymersomes. By optimizing and combining various steps from several of these established protocols, we introduce a novel Bprogressive saturation^technique that achieves increased encapsulation of functional protein in polymersomes of varying size, PEG length, and membrane thickness. We demonstrate a tradeoff between the degree of polymersome loading (i.e., weight percentage of protein-to-polymer) and the encapsulation efficiency of protein (with respect to the initial quantity) that may be achieved. Moreover, we introduce a novel proteolysis step that enables accurate quantification of the amounts of both encapsulated protein (i.e., the desired outcome) as well as that of surface-associated (i.e., nonspecifically bound) product that is obtained in polymersome suspensions. Previous studies have reported that large amounts of protein may be loaded within polymersomes and at high efficiencies, using conventional liposome encapsulation techniques. They had not, however, sought to differentiate between encapsulated and surface-associated protein, which may account for discrepancies in their observations as compared to the results presented here. Importantly, we have also demonstrated that Bprogressive saturation^enables stable encapsulation of functional protein; it may further be employed to maximize the aqueous encapsulation of many different proteins that vary over a large range of molecular weights and sizes, including those associated with therapeutically relevant antibodies and enzymes. In summary, Bprogressive saturation^is a robust, scalable, and generalizable technique for generating polymersome-encapsulated proteins in quantities and at efficiencies that may enable further translational development.
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